Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

recombinant fowlpox-prostate specific antigen vaccine

A cancer vaccine consisting of a recombinant fowlpox virus encoding human prostate-specific antigen (PSA). Administration of this agent may stimulate a cytotoxic T cell response against PSA-expressing tumor cells. Fowlpox virus is an attractive vector because its genome is easy to manipulate and it is replication incompetent in mammalian cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	fowlpox-PSA vaccine recombinant fowlpox-PSA vaccine
Abbreviation:	rF-PSA
NSC code:	694450

recombinant fowlpox-prostate specific antigen vaccine

Search NCI's Drug Dictionary